NCT00183820 - Study of Gemcitabine, Oxaliplatin, and Paclitaxel in Patients With Refractory Germ Cell Carcinoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 30, 2004

Primary Completion Date

December 31, 2015

Study Completion Date

August 31, 2016

Conditions

Testicular CancerGerm Cell Neoplasm

Interventions

DRUG

paclitaxel, gemcitabine, and oxaliplatin

"1. Paclitaxel 170 mg/m2 IV d 1 14 days~2. Gemcitabine 800 mg/m2 IV d 1 14 days~3. Oxaliplatin 100 mg/m2 IV d 1 14 days"

Trial Locations (1)

Norris Comprehensive Cancer Center, Los Angeles